$2.1 Billion is the total value of Novo Holdings A/S's 52 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VTI | VANGUARD INDEX FDStotal stk mkt | $500,838,000 | +74.1% | 1,525,550 | 0.0% | 23.88% | +68.5% | |
| SYK | STRYKER CORPORATION | $161,412,000 | +1.8% | 796,941 | 0.0% | 7.70% | -1.4% | |
| CTLT | CATALENT INC | $118,155,000 | -32.6% | 1,632,878 | 0.0% | 5.63% | -34.7% | |
| STE | STERIS PLC | $77,767,000 | -19.3% | 467,687 | 0.0% | 3.71% | -21.9% | |
| AAPL | APPLE INC | $63,763,000 | +1.1% | 461,379 | 0.0% | 3.04% | -2.1% | |
| TSM | TAIWAN SEMICONDUCTOR MFG LTDsponsored ads | $48,731,000 | -16.1% | 710,780 | 0.0% | 2.32% | -18.8% | |
| BABA | ALIBABA GROUP HLDG LTDsponsored ads | $40,061,000 | -29.6% | 500,827 | 0.0% | 1.91% | -31.9% | |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $26,914,000 | +2.3% | 317,500 | 0.0% | 1.28% | -1.0% | |
| BPMC | BLUEPRINT MEDICINES CORP | $20,866,000 | +30.5% | 316,674 | 0.0% | 1.00% | +26.3% | |
| VECT | VECTIVBIO HLDG AG | $20,037,000 | +11.1% | 3,339,484 | 0.0% | 0.96% | +7.5% | |
| PCVX | VAXCYTE INC | $19,769,000 | +10.3% | 823,705 | 0.0% | 0.94% | +6.8% | |
| INSM | INSMED INC | $16,586,000 | +9.2% | 770,000 | 0.0% | 0.79% | +5.7% | |
| LVTX | LAVA THERAPEUTICS NV | $15,206,000 | +54.9% | 3,327,312 | 0.0% | 0.72% | +50.1% | |
| TMCI | TREACE MED CONCEPTS INC | $12,984,000 | +53.9% | 588,308 | 0.0% | 0.62% | +49.2% | |
| SILK | SILK RD MED INC | $12,398,000 | +23.7% | 275,511 | 0.0% | 0.59% | +19.6% | |
| CRNX | CRINETICS PHARMACEUTICALS IN | $12,405,000 | +5.3% | 631,627 | 0.0% | 0.59% | +1.9% | |
| RPHM | RENEO PHARMACEUTICALS INC | $11,492,000 | +26.4% | 3,430,377 | 0.0% | 0.55% | +22.3% | |
| ABCL | ABCELLERA BIOLOGICS INC | $11,145,000 | -7.1% | 1,126,915 | 0.0% | 0.53% | -10.2% | |
| RCKT | ROCKET PHARMACEUTICALS INC | $10,100,000 | +16.0% | 632,822 | 0.0% | 0.48% | +12.4% | |
| KNTE | KINNATE BIOPHARMA INC | $9,748,000 | -5.2% | 815,707 | 0.0% | 0.46% | -8.3% | |
| IO BIOTECH INC | $8,883,000 | -42.0% | 3,277,932 | 0.0% | 0.42% | -43.8% | ||
| LUNG | PULMONX CORP | $8,506,000 | +13.2% | 510,555 | 0.0% | 0.41% | +9.7% | |
| SPRB | SPRUCE BIOSCIENCES INC | $6,185,000 | -21.3% | 4,514,336 | 0.0% | 0.30% | -23.8% | |
| GLTO | GALECTO INC | $4,721,000 | +9.3% | 2,497,791 | 0.0% | 0.22% | +5.6% | |
| GRTX | GALERA THERAPEUTICS INC | $4,279,000 | +33.8% | 2,459,021 | 0.0% | 0.20% | +29.9% | |
| MQ | MARQETA INC | $3,144,000 | -12.2% | 441,558 | 0.0% | 0.15% | -14.8% | |
| ALGS | ALIGOS THERAPEUTICS INC | $2,145,000 | -9.1% | 1,950,000 | 0.0% | 0.10% | -12.1% | |
| SPRO | SPERO THERAPEUTICS INC | $938,000 | +170.3% | 468,902 | 0.0% | 0.04% | +164.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VANGUARD INDEX FDS | 41 | Q3 2022 | 64.7% |
| INOGEN INC | 34 | Q2 2022 | 68.8% |
| VANGUARD INTL EQUITY INDEX F | 29 | Q4 2016 | 37.6% |
| AMICUS THERAPEUTICS INC | 22 | Q3 2023 | 4.1% |
| AKEBIA THERAPEUTICS INC | 21 | Q3 2020 | 4.8% |
| VERONA PHARMA PLC | 21 | Q2 2022 | 1.9% |
| CORVUS PHARMACEUTICALS INC | 20 | Q4 2020 | 7.1% |
| INSPIRE MED SYS INC | 20 | Q3 2023 | 1.8% |
| CABLE ONE INC | 19 | Q3 2023 | 9.7% |
| FLEXION THERAPEUTICS INC | 19 | Q3 2021 | 4.7% |
View Novo Holdings A/S's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyteir Therapeutics, Inc. | August 03, 2023 | 1,547,136 | 4.4% |
| Disc Medicine, Inc. | June 28, 2023 | 1,090,772 | 4.8% |
| Galera Therapeutics, Inc. | June 28, 2023 | 2,100,000 | 4.9% |
| VectivBio Holding AGSold out | May 26, 2023 | 0 | 0.0% |
| LanzaTech Global, Inc. | February 17, 2023 | 15,814,845 | 8.1% |
| Bolt Biotherapeutics, Inc.Sold out | January 04, 2023 | 0 | 0.0% |
| Arcellx, Inc. | December 12, 2022 | 1,750,000 | 4.0% |
| MINERVA SURGICAL INC | November 03, 2022 | 1,322,473 | 4.5% |
| Milestone Pharmaceuticals Inc. | October 24, 2022 | 1,378,538 | 4.6% |
| Galecto, Inc. | September 30, 2022 | 2,497,791 | 9.8% |
View Novo Holdings A/S's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 144 | 2024-05-10 |
| SC 13D/A | 2024-03-28 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 144 | 2024-03-18 |
| 4 | 2024-03-18 |
| SC 13D/A | 2024-03-18 |
| 144 | 2024-03-14 |
View Novo Holdings A/S's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.